Résumé
Superior Vena Cava Syndrome is the clinical manifestation of the Superior Vena Cava obstruction, with severe reduction in venous return from the head, neck and upper extremities. More than 80% cases of SVCS is nearly attributable to advanced malignancy, most commonly lung cancer. SVC syndrome is characterized by congestion and swelling of the face and upper thorax, with distended superficial chest veins. The most severe complications of SVC syndrome include Glottic edema and venous thrombosis in the central nervous system. We represent a case SVC syndrome due to Small Cell Cancer of the lung.
Résumé
The new Corona virus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). It is a highly communicable infectious disease [1]. Clinical manifestations of COVID-19 vary from asymptomatic to ARDS leading to death, it is important to differentiate between severe and non-severe cases. Early warning signs can be identified by several laboratory tests which are often expensive, time taking. Neutrophil-lymphocyte ratio (NLR), C- reactive protein (CRP) are two simple tests that can be used as markers for clinical outcome in COVID-19 patients. The aim and objectives of the study were to correlate patients clinical severity and CRP, NLR levels and to assess direct correlation between CRP levels and NLR. 101 patients who fulfilled the inclusion criteria were taken into the study. Patients are divided into mild, moderate severity based on WHO criteria and CBP, CRP were sent on the 6th/ 7th day of illness. Among the 101 patients, 93 were in mild group, 8 were in moderate group. The study group included subjects who aged between 18 years to 80 years of age. Plasma CRP levels were higher in moderate cases than in mild cases, and this difference was significant (p < 0.001). The mean NLR of moderate severity were significantly higher than those of mild cases (p-0.00003). Results showed that NLR was positively correlated with CRP levels.NLR and CRP are potential, reliable and easy-to-use predictors for deteriorating covid-19 infection. The integration of NLR and CRP may lead to improved predictions and help to triage patients at the time of hospital admission.
Résumé
Parkinson’s disease is a progressive neurodegenerative disorder, affecting the older adult. It is a syndrome consisting of classical triad of resting tremor, bradykinesia and rigidity. The triad does not include the equally important gait and postural instability problem which also constitute syndrome. Lakshanas of Vata prakopa can be seen in Parkinson’s Disease. Madhavanidana, Vangasena, Sarngadhara samhita, Basavatrajiya has quoted the pathology Kampavata- a disease condition that explains Parkinson’s disease in similar way. In short Parkinson’s disease can be compared to Kampavata. Vasti is Paramoushadha of Vata. To be specific, Musthadi rajayapana vasti is Brimhana and Vatahara in nature. So it is the best choice for a Vatavikara like Parkinson’s disease. Brimhana type of vasti plays an important role, hence Rajayapana vasti. The study is pre-post study. participants registered in IPD and OPD of Govt Ayurveda Panchakarma Hospital, Poojappura satisfying inclusion criteria were selected. After collecting baseline data, detailed history and examination were done using clinical case proforma. 15 participants were selected for the study. Musthadi rajayapana vasti was done continuously for 7 days. Assessment of efficacy was done before Vasti, after Vasti on 8th day and after follow up on 14th day by Unified Parkinson’s Disease Rating Scale. Quantitative and qualitative assessment of Vasti dravya was also done. Data were analysed according to ‘Wilcoxon signed rank test’. Based on statistical analysis Musthadi rajayapana vasti was found to be significant in reducing symptoms. Musthadi rajayapana vasti is effective in reducing severity of symptoms of Parkinson’s disease